These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 1341979

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).
    Liu T, Scallan CD, Broze GJ, Patarroyo-White S, Pierce GF, Johnson KW.
    Thromb Haemost; 2006 Jan; 95(1):68-76. PubMed ID: 16543964
    [Abstract] [Full Text] [Related]

  • 4. New treatment for hemophilia.
    FDA Consum; 2003 Jan; 37(6):5. PubMed ID: 14983810
    [No Abstract] [Full Text] [Related]

  • 5. Hemophilia care in the 21st century.
    Kempton CL, Escobar MA, Roberts HR.
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):733-40. PubMed ID: 16170890
    [No Abstract] [Full Text] [Related]

  • 6. Progressing towards optimal management of haemophilia A patients with inhibitors. Foreword.
    Tarantino MD.
    Haemophilia; 2013 Jan; 19 Suppl 1():1. PubMed ID: 23278992
    [No Abstract] [Full Text] [Related]

  • 7. Fifteen years of population based experience in Finland with a plasma-derived monoclonal purified factor VIII concentrate.
    Mäkipernaa A, von Bonsdorff L.
    Haemophilia; 2008 May; 14(3):612-4. PubMed ID: 18312362
    [No Abstract] [Full Text] [Related]

  • 8. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis.
    den Uijl IE, Fischer K.
    Thromb Haemost; 2008 May; 99(5):965; author reply 966-8. PubMed ID: 18449430
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A.
    Young JH, Liu HC, Hsueh EJ, Huang ML, Peng CT, Chen RL, Maas-Enriquez M, Achilles K.
    Haemophilia; 2009 Jul; 15(4):968-70. PubMed ID: 19473407
    [No Abstract] [Full Text] [Related]

  • 10. Evidence for the benefits of prophylaxis in the management of hemophilia A.
    Hoots WK, Nugent DJ.
    Thromb Haemost; 2006 Oct; 96(4):433-40. PubMed ID: 17003919
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Temporarily successful eradication therapy in acquired haemophilia with high inhibitor titer: a case report with a new protocol.
    Ilonczai P, Schlammadinger A, Oláh Z, Rázsó K, Bereczky Z, Boda Z.
    Thromb Haemost; 2008 Jul; 100(1):149-50. PubMed ID: 18612550
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Porcine factor VIII.
    Giangrande PL.
    Haemophilia; 2012 May; 18(3):305-9. PubMed ID: 22531020
    [No Abstract] [Full Text] [Related]

  • 17. Defining adherence to prophylaxis in haemophilia.
    Schrijvers LH, Cnossen MH, Beijlevelt-Van der Zande M, Peters M, Schuurmans MJ, Fischer K.
    Haemophilia; 2016 Jul; 22(4):e311-4. PubMed ID: 27227699
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R.
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.